NCT04896697 is a Phase 1, PHASE2 clinical trial of vilastobart (XTX101) in Advanced Solid Tumor, sponsored by Xilio Development, Inc..

Who is sponsoring NCT04896697?

NCT04896697 is sponsored by Xilio Development, Inc..

What drugs are being tested in NCT04896697?

Interventions in NCT04896697: vilastobart (XTX101), Atezolizumab, vilastobart (XTX101).

What condition does NCT04896697 study?

NCT04896697 studies Advanced Solid Tumor.

Is NCT04896697 still recruiting?

NCT04896697 is currently recruiting now. Last updated 29 May 2025.

Last reviewed 2025-05-29 · How we verify

NCT04896697

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting now Phase 1, PHASE2 Last updated 29 May 2025

What this trial tests

Phase 1, PHASE2 trial testing vilastobart (XTX101) in Advanced Solid Tumor in 136 participants. Currently enrolling.

Timeline

13 September 2021

Primary endpoint
30 March 2026

30 March 2026

Quick facts

Lead sponsor	Xilio Development, Inc.
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	136
Start date	13 September 2021
Primary completion	30 March 2026
Estimated completion	30 March 2026
Sites	19 locations across United States

Drugs / interventions tested

vilastobart (XTX101) — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →
vilastobart (XTX101) — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Xilio Development, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.
Tufail M, Jiang CH, Li N. · · 2025 · cited 82× · PMID 40739089 · DOI 10.1038/s41392-025-02280-1
Exploiting protease activation for therapy.
Bleuez C, Koch WF, Urbach C, Hollfelder F, et al · · 2022 · cited 27× · PMID 35314338 · DOI 10.1016/j.drudis.2022.03.011
The basic biology of NK cells and its application in tumor immunotherapy.
Jiang P, Jing S, Sheng G, Jia F. · · 2024 · cited 17× · PMID 39221244 · DOI 10.3389/fimmu.2024.1420205
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Jenkins KA, Park M, Pederzoli-Ribeil M, Eskiocak U, et al · · 2023 · cited 13× · PMID 38164757 · DOI 10.1136/jitc-2023-007785
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Villaruz LC, Blumenschein GR, Otterson GA, Leal TA. · · 2023 · cited 10× · PMID 36848319 · DOI 10.1002/cncr.34683
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy.
Nouruzi S, Kobelev M, Tabrizian N, Gleave M, et al · · 2025 · cited 3× · PMID 40759791 · DOI 10.1038/s44321-025-00282-8
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2
Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives.
Fei J, Cai C, Wu W, Shen H, et al · · 2026 · PMID 41950929 · DOI 10.1016/j.xcrm.2026.102728

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Xilio Development, Inc. trials

Trials by the same sponsor.

NCT05052268 — XTX202 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04896697 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xilio Development, Inc.
Last refreshed: 29 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04896697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing